Back

FASTEST

Official Title

Recombinant FVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time Trial

Study Details

The research study is being done to determine if recombinant Factor VIIa, a protein that our body makes, can slow bleeding in the brain and improve outcome, when compared to placebo.

Principal Investigator

Peter Panagos, MD

IRB Number

202010008

Eligibility

Ages 18-80
Patients with spontaneous ICH
Able to treat with study medication (rFVIIa/placebo) within 120 minutes of stroke onset or last known normal

Compensation is provided for time and effort (contact the study team for compensation amount).

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back